Isobel Ramsay1,2, Rebecca L Gorton3, Mauli Patel4, Sarita Workman5, Andrew Symes5, Tanzina Haque1, Dianne Irish1, Suranjith L Seneviratne5,6, Siobhan O Burns5,6, Emmanuel Wey7, David M Lowe5,6. 1. Department of Virology, Royal Free London National Health Service (NHS) Foundation Trust. 2. Department of Microbiology, Addenbrooke's Hospital NHS Foundation Trust, Cambridge. 3. Department of Microbiology. 4. Department of Virology, Health Services Laboratory, Royal Free Hospital. 5. Department of Clinical Immunology, Royal Free London NHS Foundation Trust. 6. Institute of Immunity and Transplantation, University College London, Royal Free Campus. 7. Department of Microbiology, Royal Free London NHS Foundation Trust, United Kingdom.
Abstract
BACKGROUND: Therapeutic immunoglobulins are used as replacement or immunomodulatory therapy, but can transmit clinically important molecules. We investigated hepatitis B virus (HBV) antibodies and galactomannan enzyme immunoassay (GM-EIA) positivity. Detection of HBV core antibody may prompt antiviral prophylaxis when commencing therapy such as rituximab; a positive GM-EIA result prompts investigation or treatment for invasive fungal disease. METHODS: We performed a cross-sectional analysis of HBV serology in 80 patients established (>6 months) on immunoglobulin therapy; prospective analysis of HBV serology in 16 patients commencing intravenous immunoglobulin (IVIG); and pre- and post-infusion analysis of GM-EIA in 37 patients receiving IVIG. RESULTS: Pre-IVIG, 9 of 80 patients tested positive for HBV surface antibody and 1 of 80 tested equivocal for HBV core antibody. On IVIG, 79 of 79 tested positive for surface antibody, 37 of 80 tested positive for core antibody, and 10 of 80 tested equivocal for core antibody. There were significant differences by product, but among patients receiving products that appear to transmit core antibody, negative results correlated with lower surface antibody titers and longer time since infusion, suggesting a simple concentration effect. There was a progressive increase with each infusion in the percentage of patients testing positive for HBV core antibody among patients newly commencing IVIG. Some patients "seroreverted" to negative during therapy. Certain IVIG products tested positive for GM-EIA and there were rises in index values in corresponding patient samples from pre- to post-infusion. Overall, 5 of 37 patient samples pre-infusion and 15 of 37 samples post-infusion tested positive for GM-EIA. CONCLUSIONS: HBV antibodies and GM-EIA positivity are common in patients receiving IVIG and confound diagnostic results.
BACKGROUND: Therapeutic immunoglobulins are used as replacement or immunomodulatory therapy, but can transmit clinically important molecules. We investigated hepatitis B virus (HBV) antibodies and galactomannan enzyme immunoassay (GM-EIA) positivity. Detection of HBV core antibody may prompt antiviral prophylaxis when commencing therapy such as rituximab; a positive GM-EIA result prompts investigation or treatment for invasive fungal disease. METHODS: We performed a cross-sectional analysis of HBV serology in 80 patients established (>6 months) on immunoglobulin therapy; prospective analysis of HBV serology in 16 patients commencing intravenous immunoglobulin (IVIG); and pre- and post-infusion analysis of GM-EIA in 37 patients receiving IVIG. RESULTS: Pre-IVIG, 9 of 80 patients tested positive for HBV surface antibody and 1 of 80 tested equivocal for HBV core antibody. On IVIG, 79 of 79 tested positive for surface antibody, 37 of 80 tested positive for core antibody, and 10 of 80 tested equivocal for core antibody. There were significant differences by product, but among patients receiving products that appear to transmit core antibody, negative results correlated with lower surface antibody titers and longer time since infusion, suggesting a simple concentration effect. There was a progressive increase with each infusion in the percentage of patients testing positive for HBV core antibody among patients newly commencing IVIG. Some patients "seroreverted" to negative during therapy. Certain IVIG products tested positive for GM-EIA and there were rises in index values in corresponding patient samples from pre- to post-infusion. Overall, 5 of 37 patient samples pre-infusion and 15 of 37 samples post-infusion tested positive for GM-EIA. CONCLUSIONS:HBV antibodies and GM-EIA positivity are common in patients receiving IVIG and confound diagnostic results.
Authors: Julie M Steinbrink; Aimee K Zaas; Marisol Betancourt; Jennifer L Modliszewski; David L Corcoran; Micah T McClain Journal: Transl Res Date: 2020-02-20 Impact factor: 7.012
Authors: Huifang Lu; Anna S Lok; Carla L Warneke; Sairah Ahmed; Harrys A Torres; Fernando Martinez; Maria E Suarez-Almazor; Jessica T Foreman; Alessandra Ferrajoli; Jessica P Hwang Journal: Lancet Haematol Date: 2018-10 Impact factor: 18.959
Authors: Carla S Walti; Elizabeth M Krantz; Joyce Maalouf; Jim Boonyaratanakornkit; Jacob Keane-Candib; Laurel Joncas-Schronce; Terry Stevens-Ayers; Sayan Dasgupta; Justin J Taylor; Alexandre V Hirayama; Merav Bar; Rebecca A Gardner; Andrew J Cowan; Damian J Green; Michael J Boeckh; David G Maloney; Cameron J Turtle; Joshua A Hill Journal: JCI Insight Date: 2021-06-08
Authors: Gabriela Schmajuk; Chris Tonner; Laura Trupin; Jing Li; Urmimala Sarkar; Dana Ludwig; Stephen Shiboski; Marina Sirota; R Adams Dudley; Sara Murray; Jinoos Yazdany Journal: Medicine (Baltimore) Date: 2017-03 Impact factor: 1.889